194 related articles for article (PubMed ID: 38615574)
1. Roles of HIF-1α signaling in Mycobacterium tuberculosis infection: New targets for anti-TB therapeutics?
Li C; Wang J; Xu JF; Pi J; Zheng B
Biochem Biophys Res Commun; 2024 Jun; 711():149920. PubMed ID: 38615574
[TBL] [Abstract][Full Text] [Related]
2. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
Kiran D; Podell BK; Chambers M; Basaraba RJ
Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
[TBL] [Abstract][Full Text] [Related]
3. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
4. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
5. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
6. The role of epigenetics, bacterial and host factors in progression of Mycobacterium tuberculosis infection.
Marimani M; Ahmad A; Duse A
Tuberculosis (Edinb); 2018 Dec; 113():200-214. PubMed ID: 30514504
[TBL] [Abstract][Full Text] [Related]
7. Host-Pathogen Interaction as a Novel Target for Host-Directed Therapies in Tuberculosis.
Abreu R; Giri P; Quinn F
Front Immunol; 2020; 11():1553. PubMed ID: 32849525
[TBL] [Abstract][Full Text] [Related]
8. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
de Wet TJ; Warner DF; Mizrahi V
Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia inducible factor signaling modulates susceptibility to mycobacterial infection via a nitric oxide dependent mechanism.
Elks PM; Brizee S; van der Vaart M; Walmsley SR; van Eeden FJ; Renshaw SA; Meijer AH
PLoS Pathog; 2013; 9(12):e1003789. PubMed ID: 24367256
[TBL] [Abstract][Full Text] [Related]
10. New approaches to tuberculosis--novel drugs based on drug targets related to toll-like receptors in macrophages.
Tomioka H
Curr Pharm Des; 2014; 20(27):4404-17. PubMed ID: 24245765
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance mechanisms and novel drug targets for tuberculosis therapy.
Islam MM; Hameed HMA; Mugweru J; Chhotaray C; Wang C; Tan Y; Liu J; Li X; Tan S; Ojima I; Yew WW; Nuermberger E; Lamichhane G; Zhang T
J Genet Genomics; 2017 Jan; 44(1):21-37. PubMed ID: 28117224
[TBL] [Abstract][Full Text] [Related]
12. New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics.
Hawn TR; Shah JA; Kalman D
Immunol Rev; 2015 Mar; 264(1):344-62. PubMed ID: 25703571
[TBL] [Abstract][Full Text] [Related]
13. Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?
Park HE; Lee W; Shin MK; Shin SJ
Front Immunol; 2021; 12():703060. PubMed ID: 34262571
[TBL] [Abstract][Full Text] [Related]
14. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
15. TB drug development: immunology at the table.
Nathan C; Barry CE
Immunol Rev; 2015 Mar; 264(1):308-18. PubMed ID: 25703568
[TBL] [Abstract][Full Text] [Related]
16. Recent updates on drug resistance in Mycobacterium tuberculosis.
Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice.
Koo MS; Manca C; Yang G; O'Brien P; Sung N; Tsenova L; Subbian S; Fallows D; Muller G; Ehrt S; Kaplan G
PLoS One; 2011 Feb; 6(2):e17091. PubMed ID: 21364878
[TBL] [Abstract][Full Text] [Related]
18. Altered drug efflux under iron deprivation unveils abrogated MmpL3 driven mycolic acid transport and fluidity in mycobacteria.
Pal R; Hameed S; Fatima Z
Biometals; 2019 Feb; 32(1):49-63. PubMed ID: 30430296
[TBL] [Abstract][Full Text] [Related]
19. Host-pathogen interactions in latent Mycobacterium tuberculosis infection: identification of new targets for tuberculosis intervention.
Lin MY; Ottenhoff TH
Endocr Metab Immune Disord Drug Targets; 2008 Mar; 8(1):15-29. PubMed ID: 18393920
[TBL] [Abstract][Full Text] [Related]
20. Dual role of hypoxia-inducible factor 1 α in experimental pulmonary tuberculosis: its implication as a new therapeutic target.
Baay-Guzman GJ; Duran-Padilla MA; Rangel-Santiago J; Tirado-Rodriguez B; Antonio-Andres G; Barrios-Payan J; Mata-Espinosa D; Klunder-Klunder M; Vega MI; Hernandez-Pando R; Huerta-Yepez S
Future Microbiol; 2018 Jun; 13():785-798. PubMed ID: 29848058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]